Leukopenia during Treatment with First-Line Anti-Tuberculosis Medication

Publisher： Karger

E-ISSN： 1423-0356|72|6|660-661

ISSN： 0025-7931

Source： Respiration, Vol.72, Iss.6, 2005-12, pp. : 660-661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Adjusted Indirect Treatment Comparison of the Bioavailability of WHO‐Prequalified First‐Line Generic Antituberculosis Medicines

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 5, 2014-11 ,pp. : 580-588

John Wiley & Sons Inc

Access to resources Recommend Favorite

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first‐line treatment of patients with advanced breast cancer: Phase 3 randomized trial

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3412-3421

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

State-of-the-Art First-Line Treatment of Ovarian Cancer

By  

Oncology Research and Treatment, Vol. 26, Iss. 5, 2003-11 ,pp. : 446-450

Karger

Access to resources Recommend Favorite

Response to Empirical Anti-Tuberculosis Treatment in Patients with Sputum Smear-Negative Presumptive Pulmonary Tuberculosis

By  

Respiration, Vol. 72, Iss. 4, 2005-07 ,pp. : 369-374

Karger

Access to resources Recommend Favorite